Results 21 to 30 of about 15,628 (311)

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives

JMIR Medical Informatics, 2014
BackgroundThe Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) is a repository of spontaneously-reported adverse drug events (ADEs) for FDA-approved prescription drugs.
Polepalli Ramesh, Balaji, Belknap, Steven M, Li, Zuofeng, Frid, Nadya, West, Dennis P, Yu, Hong   +5 more
doaj   +1 more source

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database [PDF]

, 2013
Background: Drug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden. Objective: As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US ...
A Bate, A Clarke, A Pariente, AK Chung, Ariola Koci, B Darpo, BJ Drew, C Meyer-Massetti, DM Roden, DW Hough, E Poluzzi, E Poluzzi, E Poluzzi, E Raschi, E Raschi, Edoardo Spina, Elijah R. Behr, Elisabetta Poluzzi, Emanuel Raschi, EP Puijenbroek van, ER Behr, F Ponti De, F Ponti De, F Rani, Fabrizio De Ponti, GC Alexander, GK Isbister, H Verdoux, J Nielsen, J Papay, K Jolly, K Titier, LC Wittkampf, LS Schneider, Miriam Sturkenboom, NP Tatonetti, P Kannankeril, P Manu, P Vigneault, RC Owens Jr, RR Shah, S Dhillon, S Hennessy, S Kongsamut, S Leucht, SM Straus, Ugo Moretti, W Crumb, W Crumb, WA Ray, WA Ray, WJ Crumb Jr, WP Stephenson, Y Suzuki   +53 more
core   +4 more sources

Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis

Frontiers in Pharmacology, 2018
Multiple data sources are preferred in adverse drug event (ADEs) surveillance owing to inadequacies of single source. However, analytic methods to monitor potential ADEs after prolonged drug exposure are still lacking.
Liwei Wang, Majid Rastegar-Mojarad, Zhiliang Ji, Sijia Liu, Ke Liu, Sungrim Moon, Feichen Shen, Yanshan Wang, Lixia Yao, John M. Davis III, Hongfang Liu   +10 more
doaj   +1 more source

Provenance-Centered Dataset of Drug-Drug Interactions [PDF]

, 2015
Over the years several studies have demonstrated the ability to identify potential drug-drug interactions via data mining from the literature (MEDLINE), electronic health records, public databases (Drugbank), etc.
A Callahan, A Gottlieb, B Mons, DS Wishart, J Lazarou, K Haerian, L Zhang, M Dumontier, NP Tatonetti, P Avillach, P Groth, RL Bushardt, S Vilar, SV Iyer, T Kuhn   +14 more
core   +3 more sources

Publicity and reports of behavioral addictions associated with dopamine agonists [PDF]

, 2015
Background The development of behavioral addictions (BAs) in association with dopamine agonists (DAs, commonly used to treat Parkinson’s disease) has been reported.
Gendreau, Katherine E., Potenza, Marc N.
core   +1 more source

Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics

Frontiers in Psychiatry, 2021
Introduction: The latest decade, an emerging issue has been the abuse potential of the gabapentinoids pregabalin and gabapentin. The aim of our study was to assess this safety signal combining two different methods of surveillance: search analytics big ...
Georgios Papazisis, Dimitrios Spachos, Spyridon Siafis, Niki Pandria, Eleni Deligianni, Ioannis Tsakiridis, Antonios Goulas   +6 more
doaj   +1 more source

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project [PDF]

, 2015
Introduction: Spontaneous reporting systems (SRSs) are pivotal for signal detection, especially for rare events with a high drug-attributable component, such as torsade de pointes (TdP).
Antoniazzi, S. (Stefania), Garbe, C. (Claus), Hazell, L. (Lorna), Koci, A. (Ariola), Moretti, U. (Ugo), Pariente, A. (Antoine), Perina, L. (Luisella), Poluzzi, E. (Elisabetta), Ponti, F. (Fabrizio) de, Raschi, E. (Emanuel), Salvo, F. (Francesco), Sturkenboom, M.C.J.M. (Miriam), Suling, M. (Marc)   +12 more
core   +3 more sources

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis

JMIR Public Health and Surveillance, 2020
BackgroundAdverse drug reactions (ADRs) can occur any time someone uses a medication. ADRs are systematically tracked and cataloged, with varying degrees of success, in order to better understand their etiology and develop methods of prevention.
Zhou, Zeyun, Hultgren, Kyle Emerson
doaj   +1 more source

Translational high-dimensional drug Interaction discovery and validation using health record databases and pharmacokinetics models [PDF]

, 2017
Polypharmacy increases the risk of drug-drug interactions (DDI's). Combining epidemiological studies with pharmacokinetic modeling, we detected and evaluated high-dimensional DDI's among thirty frequent drugs.
Chiang, Chien-Wei, Li, Lang, Ning, Xia, Quinney, Sara K., Shen, Li, Wang, Lei, Wang, Xueying, Zhang, Pengyue, Zhang, Shijun   +8 more
core   +1 more source

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study

Frontiers in Pharmacology, 2023
Importance: Checkpoint inhibitor pneumonitis (CIP) is a rare but serious adverse event that may impact treatment decisions. However, there is limited information comparing CIP risks between immune checkpoint inhibitor (ICI) monotherapy and combination ...
Huixia Li, Yifan Zheng, Peihang Xu, Zimu Li, Yukun Kuang, Xiaoqing Feng, Junhao He, Jia Li, Xiao Chen, Lihong Bai, Ke-Jing Tang, Ke-Jing Tang   +11 more
doaj   +1 more source